Date: 2026-02-23 Quarter: Q3 FY25 (Sep-2025, reported Nov 12 2025) Market cap: $3.2B | EV/TTM Rev: ~3.8x | Revenue growth: 74.0% YoY Prior analysis: 2026-02-21 (same quarter, pre-stage outputs)
ARX delivered a genuinely exceptional Q3: revenue +74% YoY to $267.4M, EBITDA at an all-time high of $105M (39.3% margin), adjusted net income up 320% YoY to 79.8M.TheGAAPlossof−1,367M is a one-time non-cash IPO profit interest distribution — irrelevant to operating performance. The stock is a broken IPO trading at 3.8x TTM revenue, 75% below analyst consensus target, while a sophisticated value fund (Keenan Capital) just built a $51M position. The central thesis is intact. The central risk is the pending FY26 EBITDA margin compression from mix shift to third-party capacity — which is strategically correct but will create a narrative headwind for at least 4 quarters.
Conviction: 3.5/5
| Criterion | Threshold | ARX | Verdict |
|---|---|---|---|
| Revenue YoY growth | >30% | 74.0% | Pass |
| Gross margin | >60% | N/A (insurance model) | Exempt |
| Revenue per quarter | >$50M | $267.4M | Pass |
| Data availability | 4+ quarters | 7 quarters | Pass (note: <12Q minimum; IPO Jul 2025) |
| Share dilution | <10% annual | ~24% at IPO (165.8M→206.1M) | Conditional — one-time structural, not ongoing |
| GAAP profitability trajectory | Improving or positive | -$1,367M (one-time non-cash) | Conditional — non-GAAP adj net income $79.8M, +320% YoY |
Overall: Qualified. Gross margin exemption appropriate for insurance marketplace model (revenue = commissions + earned premium + investment income, not SaaS-style gross profit). IPO-related dilution and one-time GAAP charge are structural noise, not operating reality.
| Factor | Rating | Detail |
|---|---|---|
| Growth | Strong | 74.0% YoY revenue; 3rd consecutive quarter of acceleration from 38.9% base |
| Trajectory | Accelerating | 38.9% → 68.4% → 74.0% YoY; sustained and widening from a growing absolute base |
| Margins | High (transitioning) | EBITDA 39.3% at all-time high; guided to compress sharply in FY26 due to mix shift (deliberate, not deterioration) |
| Dominance | Strong | #3 non-exclusive MGA by premiums; exclusive/majority capacity for all 265 members; 125M+ row proprietary data moat; 5-year curated member track records |
| Valuation | Cheap | 3.8x TTM revenue; ~11.9x FY26E EBITDA; 75% below 8-analyst consensus target; broken IPO at ~48% below issue price |
| Special | Present | Broken IPO mispricing + one-time GAAP charge obscuring operating performance; Keenan Capital $51M buy at current prices; E&S market structural tailwind described by CEO as "permanent" |
7 quarters available (IPO Jul 2025; <12Q minimum not met — noted).
| | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | | | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | |---|---|---|---|---|---|---|---| | Revenue ($M) | 128.1 | 130.1 | 153.7 | 190.7 | 178.0 | 219.1 | 267.4 | | QoQ % | — | +1.6% | +18.1% | +24.1% | -6.7% | +23.1% | +22.0% | | YoY % | — | — | — | — | +38.9% | +68.4% | +74.0% |
| | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | | | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | |---|---|---|---|---|---|---|---| | EBITDA ($M) | 27.5 | 13.0 | 26.1 | 46.4 | 42.8 | 63.5 | 105.0 | | EBITDA margin % | 21.5% | 10.0% | 17.0% | 24.3% | 24.0% | 29.0% | 39.3% |
| | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | | | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | |---|---|---|---|---|---|---| | Net income GAAP (M)|−9.2|9.4|20.1|7.8|13.1|−1, 367.0||Netincomeadj(M) | — | 19.0 | — | — | 28.6 | 79.8 | | Adj net margin % | — | 12.4% | — | — | 13.1% | 29.8% | | Shares diluted (M) | 165.9 | 166.2 | — | 166.2 | 166.2 | 206.1 | | Adj EPS diluted | — | — | — | — | — | $0.38 |
| | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | | | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | |---|---|---|---|---|---|---|---| | EWP (M)|583.8|756.8|888.4|879.4|985.2|1, 072.3|1, 042.9||GWP(M) | 551.1 | 727.0 | 795.5 | 832.7 | 874.0 | 911.3 | 791.9 | | 3P DWP ($M) | 0 | 0 | 0 | 0 | 0 | ~245 | 333.3 | | 3P % of EWP | 0% | 0% | 0% | 0% | 0% | ~27% | 32% | | Gross loss ratio | 52.1% | 54.7% | 51.8% | — | 53.3% | 50.5% | 50.1% | | Net loss ratio | 65.2% | 82.8% | 66.9% | — | 71.7% | 72.7% | 61.9% |
| | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | | | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | |---|---|---|---|---|---|---|---| | Total members | 170 | 186 | 204 | 217 | 232 | 248 | 265 | | Independent members | 126 | 142 | 158 | 170 | 185 | 201 | 220 | | Net adds (total) | — | +16 | +18 | +13 | +15 | +16 | +17 |
Context: Q2 FY25 showed 68.4% YoY revenue growth, EBITDA margin of 29.0%, NRR of 151%, and 3P capacity at ~27% of EWP. The primary question entering Q3 was whether growth acceleration would sustain and whether EBITDA expansion was real or seasonal.
| Metric | Expected | Actual | Verdict |
|---|---|---|---|
| Revenue YoY growth | ~55-65% (moderating from Q2's 68.4%) | 74.0% | Beat — acceleration continued |
| Revenue ($M) | ~$235-250M | $267.4M | Beat ~$17-30M |
| EBITDA margin | ~28-32% (incremental expansion) | 39.3% reported / 24.7% underlying | Inflated — 39Mnon − recurringinvestmentgainincludedinreportedEBITDA; ex − gain 66M at ~24.7%, in line with Q2 trend |
| EBITDA ($M) | ~$65-80M | 105.0Mreported/ 66M underlying | Do not use 39.3% margin as baseline — underlying is ~24.7%, which is the correct Q4 comp |
| Adj net income | ~$35-45M | $79.8M | Beat — 320% YoY, +179% QoQ (adj NI not affected by $39M gain disclosure) |
| EWP | ~$1.0-1.1B (flat to slight growth) | $1,042.9M | In line |
| 3P % of EWP | ~28-32% (gradual expansion) | 32% | In line |
| Member additions | +15-18 | +17 | In line |
| NRR | ~140-150% (some continued normalization) | 135% | Miss — declined more than expected |
| Loss ratios | Stable | Gross 50.1%, Net 61.9% | Beat — improving YoY and QoQ |
Delta assessment: The $39M non-recurring investment gain in Q3 requires a significant asterisk on the EBITDA beat. Reported EBITDA of 105M(39.366M at ~24.7%, consistent with Q2 FY25 trajectory. The adj net income figure (79.8M)isthecleanermetricandrepresentsagenuinebeat : ExchangeServicesrevenueat 85M (take rate expanded 7.1% → 8.0%), direct commissions +152% YoY, and exchange pipeline disclosed at 3Bannualized(1.8B under contract) are all substantive positives. The NRR decline (151%→135%) and the need to adjust EBITDA for a non-recurring item are the two qualifiers on an otherwise strong quarter.
ARX's equivalent of SaaS leading indicators are EWP volume growth, member counts, NRR, 3P capacity share, and direct commission growth.
Bullish signals:
Bearish signals:
Divergence verdict: Leading indicators are in genuine bullish-bearish tension. The monetization of 3P expansion (direct commissions +152%) is a bullish signal. NRR deterioration is a bearish signal. The central question: does the direct commission line grow fast enough to offset NRR dilution as mix shifts to 3P? Early data (Q3 revenue beat) suggests yes, but Q4 EBITDA guidance says the transition will create earnings volatility. Not a divergence that signals crisis — it is a deliberately managed transition with known, manageable near-term margin costs.
Broken IPO, functioning business. Stock is down ~48% from the 21IPOprice( 10.95 current). The $1.367bn GAAP loss (one-time non-cash profit interest distribution at IPO) triggered retail selling into a thin market. Institutional analysts with 8/8 Buy ratings and $19+ targets have not cut. (Source: public.com analyst consensus, Seeking Alpha, Motley Fool/Keenan Capital coverage)
Sophisticated money is buying. Keenan Capital bought 3.14M shares (~$51.3M) at current prices — 9.35% of their fund AUM. This is a high-conviction, concentrated bet from a firm that did the work. (Source: Motley Fool/SEC filing, Feb 2026)
Governance is the primary investor alignment risk, not business quality. Altamont Capital holds 77% of voting power on 41% of economics via Class B super-voting shares. Messerli Capital (independent analyst) downgraded to "too hard" in January 2026 specifically because of this, acknowledging the business model is attractive. This is a legitimate concern — public shareholders have no meaningful vote on strategic decisions. (Source: Messerli Capital Substack, Jan 2026)
CEO's PXRE failure requires context. Jeff Radke led PXRE Group (Bermuda cat reinsurer) which collapsed under 2005 hurricane losses. The Accelerant model — diversified specialty, no catastrophe concentration — is the deliberate opposite of PXRE's design. His 30-year industry network and Altamont's continued sponsorship are positive signals; the PXRE episode is not disqualifying. (Source: FF News profile, Insurance Business Mag, CNBC IPO interview)
Platform data moat is real but underwriting outcomes lag. 125M+ proprietary data rows, 57k+ attributes, AI risk scoring at the MGA underwriting interface. The flywheel is architecturally sound. However, net loss ratio ~73% (2024) still trails Kinsale Capital's ~mid-50s. The data advantage has not yet translated to best-in-class underwriting performance. (Source: Messerli Capital analysis, InsurTech Insights, BusinessWire)
Employee culture needs post-IPO repair. Glassdoor 3.3/5 (19 reviews), 53% recommend, career development weakest category (2.8/5). Fast headcount growth (24% in ~6 months post-IPO, 451 → 559 employees) typically precedes culture strain. Competitive pay and remote-first help retention, but leadership structure is described as weak. (Source: Glassdoor)
E&S market tailwind confirmed as structural. Radke describes the regulatory migration to E&S as "permanent." Independent market data shows Accelerant ranked #3 among non-exclusive MGA platforms by premiums written ($1.4bn DWP in 2024). Industry is growing and regulatory environment is supportive. (Source: BeInsure MGA Rankings, Insurance Business Mag)
Claims friction at policyholder layer. Trustpilot reviews (thin sample) flag extended claims resolution times. This is a tail risk for member quality/reputation — ARX is one step removed (the MGA bears the claims relationship) but poor member underwriting quality directly damages ARX's portfolio. (Source: Trustpilot)
| Metric | Current | Implied at Analyst Target ($19) | Peer / Benchmark | Assessment |
|---|---|---|---|---|
| Market cap | $3.2B | ~$5.5B | — | — |
| EV/TTM Revenue | ~3.8x | ~6.5x | RYAN ~3x, specialty InsurTech comps 4-8x | Cheap |
| P/FY26E EBITDA | ~11.9x | ~20.5x | High-quality insurers 12-20x | Fair-to-Cheap |
| P/Adj NI (annualized) | ~10x ($319M ann. adj NI) | ~17x | Growth insurtechs 15-25x | Cheap |
| Stock vs. IPO price | -48% ($10.95 vs $21.00) | -10% vs IPO | — | Broken IPO discount |
Key valuation consideration: ARX's TTM revenue of $855M includes significant owned capacity revenue (net earned premium, investment income) that will shrink as a % of total as 3P mix rises. FY26 EBITDA guidance of $269M on EWP of $5B+ implies management is deliberately compressing the near-term earnings multiple in exchange for scaling the higher-quality, capital-light exchange fee revenue stream. At $3.2B market cap and $269M FY26E EBITDA, you are paying ~11.9x for a business that should structurally re-rate to 15-20x as the 3P mix demonstrates repeatability. The discount to analyst targets (75%) is unusually wide for a 74%-growing profitable company.
What's priced in at current levels: The market is pricing in either (a) the FY26 EBITDA compression is worse than guided and/or permanent, or (b) governance risk makes the equity uninvestable for institutional flows. Neither of these is a business quality verdict.
Secular tailwind: E&S (Excess & Surplus Lines) specialty insurance is the fastest-growing segment of US P&C. Regulatory complexity and risk diversification needs push more risk out of admitted markets into E&S permanently — CEO Radke characterizes this as structural, not cyclical. The market is moving to ARX, not ARX chasing the market.
Platform architecture: True two-sided marketplace. Left side: 265 MGA members with 3-5 year curated track records, bound to ARX by exclusive or majority capacity agreements. Right side: owned insurers + growing roster of 17 third-party capacity providers. The data platform (InSightFull / Accelerant Digital Platform) sits in the middle, providing AI risk scoring, real-time underwriting analytics, and 125M+ row exposure database fed into member systems via API.
Flywheel assessment: More premium volume → richer exposure data → better ML models → more accurate pricing → attracts more and better capital providers → enables member growth → more premium. This logic is architecturally sound and is consistent with observed NRR of 135% (strong even while normalizing). The flywheel is still in early innings — 265 members vs. addressable universe of thousands of specialty MGAs globally (operating in 22 countries, 500+ specialty products).
Platform vs. point solution verdict: Platform. Multi-product, global, ecosystem — not a point solution. The exchange model, data layer, and capital provision across owned + third-party capacity are interdependent and non-replicable quickly. Moat durability is high if execution holds.
TAM penetration: Low. Accelerant's $4B+ annualized EWP represents a small fraction of the global specialty E&S market (US E&S premiums alone exceeded $100B in 2024). Long runway.
FY26 EBITDA compression narrative. Q4 FY25 EBITDA guided at $57-62M (vs Q3's $105M) and FY26 full-year at $269M. The market will headline-read this as a ~36% EBITDA decline sequentially. Most investors will not immediately grasp that this is deliberate mix-shift engineering. Expect significant near-term price volatility and potential multiple compression as the story plays out.
NRR trajectory. Two data points (151% → 135%, -16pp QoQ) is not a trend, but the direction is down and the mechanism is structural (3P capacity earns less per premium dollar for ARX). If NRR drops below 120% by mid-FY26, the platform's per-member monetization thesis weakens materially.
Governance structure. Altamont's 77% voting / 41% economic interest via Class B super-voting shares means public shareholders have no governance recourse. All strategic decisions — capital allocation, M&A, dividend policy, executive compensation — flow through Altamont. This is a structural overhang that limits institutional ownership eligibility and permanently caps the multiple relative to comparable publicly-governed companies.
Underwriting quality risk. Net loss ratio ~73% (2024) trails best-in-class (~50s). As EWP scales rapidly via 3P capacity and independent member additions, maintaining underwriting discipline becomes harder. A deterioration in combined ratios would directly impair ARX's ability to attract third-party capacity providers (who can redirect to better-underwritten alternatives).
CEO execution track record. PXRE failure (2005-2007) under Radke is on record. While the Accelerant model deliberately avoids PXRE's catastrophe exposure, Radke has now taken a company through IPO for the first time and faces public-company scaling challenges he has not previously navigated. Post-IPO leadership inexperience (Glassdoor: poor internal structure, weak career development) is an early yellow flag.
Q4 FY25 earnings (February 2026, expected). First full quarter under IPO scrutiny with explicit EWP and EBITDA guidance ($1.06-1.1B EWP, $57-62M EBITDA). If 3P DWP approaches the $415-430M guide, it confirms the insurer onboarding ramp. Any upside to the EBITDA guide resets FY26 expectations positively.
FY26 EBITDA margin stabilization evidence. The moment management demonstrates that FY26 EBITDA margins are bottoming (not continuing to compress), the stock re-rates. This will likely come in Q2 or Q3 FY26 when the mix shift math becomes clearer.
New third-party insurer announcements. From 0 to 17 in two quarters — each new insurer adds to the capital side of the exchange and increases EWP capacity without ARX deploying additional balance sheet. Announcements of named A-rated carriers joining the platform are high-signal catalysts.
NRR stabilization. A Q4 FY25 or Q1 FY26 NRR reading at or above 135% stops the narrative of per-member revenue compression and restores confidence in exchange fee monetization.
Altamont secondary / governance simplification. Any move by Altamont to reduce voting control (secondary offering, dual-class sunset provision, or conversion to single-class) would be a significant institutional accessibility event. Messerli Capital explicitly cited this as the gating factor for their investment.
Position disclosure: No position held.